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Abstract
Background: The acquisition and development of infant gut microbiota can be influenced by numerous factors, of
which early antibiotic treatment is an important one. However, studies on the effects of antibiotic treatment in early
life on clinical outcomes and establishment and development of the gut microbiota of term infants are limited.
Disturbed microbiota composition is hypothesized to be an underlying mechanism of an aberrant development of
the immune system. This study aims to investigate the potential clinical and microbial consequences of empiric
antibiotic use in early life.
Methods/Design: 450 term born infants, of whom 150 are exposed to antibiotic treatment in early life and 300 are
not (control group), are included in this observational cohort study with a one-year follow-up. Clinical outcomes,
including coughing, wheezing, fever >38 °C, runny nose, glue ear, rash, diarrhea and >3 crying hours a day, are
recorded daily by parents and examined by previously defined doctor’s diagnosis. A blood sample is taken at
closure to investigate the infant’s vaccination response and sensitization for food and inhalant allergens. Fecal
samples are obtained at eight time points during the first year of life. Potential differences in microbial profiles of
infants treated with antibiotics versus healthy controls will be determined by use of 16S-23S rRNA gene analysis
(IS-pro). Microbiota composition will be described by means of abundance, diversity and (dis)similarity. Diversity is
calculated using the Shannon index. Dissimilarities between samples are calculated as the cosine distance between
each pair of samples and analyzed with principal coordinate analysis. Clinical variables and possible associations are
assessed by appropriate statistics.
Discussion: Both clinical quantitative and qualitative microbial effects of antibiotic treatment in early life may be
demonstrated. These findings can be important, since there is evidence that manipulation of the infant microbiota
by using pre- or probiotics can restore the ecological balance of the microbiota and may mitigate potential
negative effects on the developing immune system, when use of antibiotics cannot be avoided.
Trial registration: ClinicalTrials.gov NCT02536560. Registered 28 August 2015.
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Background
The fetal intestine is (virtually) sterile, however, from
birth onwards, the infant intestine becomes colonized
with a wide variety of microorganisms [1]. The interaction
between the host and its microbiota contributes funda-
mentally to overall health [2, 3]. For example, the micro-
bial ecosystem provides the host with valuable metabolic
features, such as metabolism of otherwise indigestible
carbohydrates, xenobiotic metabolism, and production of
essential metabolites such as vitamin K [4, 5]. Further-
more, the colonizing microorganisms play a key role in
driving post-natal maturation of the infant gut and devel-
opment of the mucosal immune system [6–10].
Disturbance of the microbial colonization patterns
early in life can lead to long-lasting host effects and
eventually disease. Aberrancies in microbial colonization
patterns or distortion of the microbial ecology early in
life might predispose the infant to the development of
immune-mediated diseases. The gut microbiota has been
associated with T-helper 2 (Th2) type diseases like allergy,
wheezing and asthma, and also with T-helper 1 (Th1) type
diseases, like inflammatory bowel disease, diabetes and
obesity [11–24]. Also in non-immune mediated diseases,
like infantile colic or irritable bowel syndrome, the fecal
microbiota composition was found to be different from
healthy controls [25, 26].
A range of factors can influence the composition of
the intestinal microbiota and its establishment, like
mode of delivery, feeding mode, contact with parents,
siblings, and nursing and/or hospital staff when appro-
priate [27–29]. Antibiotic treatment during the early
postnatal period, that has become common in modern
obstetric and neonatal practice [15], is one of the im-
portant factors that can influence maturation of the in-
fant gut microbiota and thus increase the risk of disease
[11, 24]. A systematic review in 2011 of longitudinal
studies on the effects of infant antibiotic use showed a
higher risk for subsequent development of wheezing
and/or asthma [30]. Other studies have shown an associ-
ation between infant antibiotic exposure and growth rate
and development of adiposity [31–33].
Relatively few studies have determined the direct ef-
fects of antibiotics on the composition of gut microbiota
and/or addressed the mechanisms underlying this asso-
ciation [13, 29, 34]. Initial studies were based on culture-
dependent techniques, but altered intestinal microbiota
in antibiotic treated infants could already be identified
by these relatively limited techniques [35, 36]. In the last
few years, the development of culture-independent
(molecular) approaches for studying the intestinal
microbiota composition has changed and advanced our
original perspective and insight into the impact of the
composition of the microbiome [37, 38]. By using molecu-
lar fingerprinting and determination of 16S rRNA genes
(by quantitative polymerase chain reaction, qPCR),
overgrowth of Enterococci and arrested growth of Bifi-
dobacterium in infants exposed to antibiotics in the
first week of life has been described [34].
Overall, evidence is growing that an aberrant micro-
biota composition as a result of antibiotic treatment can
have clinical effects, but more robust studies are needed
with a higher number of patients to elucidate the exact
effects of antibiotics on the developing microbiota and
its association with health in the first year of life. This
study therefore aims to investigate the potential clinical
and microbial consequences of empiric antibiotic use
in early life by following a large cohort of 150 treated
and 300 untreated infants and compare them with
respect to their health status as well as their develop-
ing gut microbiota.
Methods/Design
Study design and population
A prospective, observational cohort study with a one-
year follow-up is currently conducted to determine the
clinical effects and impact on the gut microbiota com-
position of empiric antibiotic use in early life. Infants are
recruited from the maternity wards and neonatal wards
of four teaching hospitals in the Netherlands: the St.
Antonius Hospital in Nieuwegein, the Tergooi Hospital
in Blaricum, the Gelre Hospitals in Apeldoorn and the
Meander Medical Center in Amersfoort. This study was
approved by the joined Medical Ethics Committee
(VCMO) of the St Antonius Hospital and Meander Medical
Center (nowadays MEC-U: Medical Research Ethics
Committees United (Nieuwegein)). In The Netherlands,
since 2013 studies only need to be approved by one Ethics
Committee. Subsequently, for other participating centers,
proof of local feasibility needs to be given. The approved
protocol was consequently checked for local feasibility and
expertise at Tergooi Hospital and Gelre Hospitals and
permission for study implementation was obtained by the
respective boards of directors. The study is performed in
accordance with the ethical standards laid down in the
1964 Declaration of Helsinki and its later amendments.
All parents of term infants (≥ 36 weeks of gestational
age) who stay in the hospital for at least 24 h, are
approached for participation in the study.
In total 150 infants, treated with antibiotics because of
(a high suspicion of ) a perinatal infection during the first
week of life, will be recruited. The control group comprises
300 healthy newborns, born in the hospital and needing
clinical observation for 24–48 h for several reasons like
maternal comorbidity, low probability of neonatal infec-
tion, blood sugar monitoring, meconium containing amni-
otic fluid, or delivery by caesarean section. For a balanced
composition of the control group, as much as pos-
sible infants that are suspected to have a neonatal
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infection but for whom watchful waiting is allowed
(and no antibiotic treatment has to be started) will
be included.
Inclusion and exclusion criteria
Inclusion criteria
1. Term-born babies (≥ 36 weeks gestational age)
2. (Short) stay on maternal ward or admission to
neonatal ward because of antibiotic treatment
3. Signed informed consent by the parents
Exclusion criteria
1. Congenital illness or malformations
2. Severe perinatal infections for which transfer to the
neonatal intensive care unit is needed
3. Maternal probiotic use ≤ six weeks before delivery
4. Insufficient knowledge of the Dutch language.
Infants suspected of neonatal infection will be treated
with antibiotics according to the local hospital protocols.
All hospitals use gentamycin in combination with either
penicillin, amoxicillin or amoxicillin/clavulanic acid.
During the study period, type of feeding is closely moni-
tored, as parents monthly report the type of feeding on
the calendar list (breast- or formula feeding). Parents are
free in their choice of feeding regime, and after six
months infants will be on solid food, but not all the in-
fants in the study will have the exact same diet as this is
neither feasible nor ethical. Mother’s intake of antibiotics
or drugs during pregnancy, delivery and during breast-
feeding (if applicable) will be recorded. Delivery/hospital
data will be extracted from patient records.
All parents have to give informed consent prior to inclu-
sion in the study. Follow up continues during the first year
of life, in which parents collect and store eight fecal sam-
ples of their infant. Parents are also asked to collect a fecal
sample of their child around the 2nd birthday and they
give permission for a possible approach for a follow-up in
about 5–6 years.
Aims
Healthy newborns born in the hospital, observed for low
probability of neonatal infection will be compared to
newborns exposed to antibiotic therapy in early life (first
1–2 weeks) by investigating potential differences in fecal
microbiota composition. For this purpose fecal bacterial
composition and diversity is determined at eight time
points during the first year of life, from birth on: day
one (T1), day two (T2), one week (T3), two weeks (T4),
one month (T5), three months (T6), six months (T7),
one year (T8). An overview of the sample time points
and outcomes is shown in Fig. 1.
Potential differences in proportions (abundance and
diversity) of intestinal bacterial groups (phyla) and spe-
cies in antibiotic treated infants versus healthy controls
will be determined by use of 16S-23S rRNA gene analysis.
Secondly, we investigate differences in clinical outcomes
between infants treated with antibiotics and controls. We
evaluate incidences of atopic dermatitis (eczema), food
allergy, upper respiratory tract infections (URTI), lower
respiratory tract infections (LRTI), gastrointestinal infec-
tions (GITI) and excessive crying, prospectively assessed
by parental reports and retrospectively assessed by doctor’s
diagnoses. The clinical endpoints will be linked to the de-
veloping intestinal microbiota during the first year of life.
Body mass index and standard deviation (SD)-scores are
calculated from individual weight and height curves.
Parents of all included infants will report the use of
antibiotics (type of antibiotics and duration of treatment)
during the complete study period (i.e. the first year of
life) on the calendar lists. Moreover, (the type of ) pre-
scribed antibiotics will be investigated at the end of the
initial study period by approaching the infant’s pharmacy
on medications used in the first year of life. Parents are
also asked to report the moment of stool collection
(date) on the collection vial, so the investigators can
calculate the time between antibiotic treatment and stool
sample collection. We hypothesize that in early life anti-
biotic treated infants develop more eczema during their
first year than non-antibiotic treated infants (healthy
controls). We also expect an increase in incidence of
(parental reported as well as doctor’s diagnosed) food
allergy, respiratory tract infections (RTI’s) and gastro-
intestinal tract infections (GITI’s) in infants treated with
antibiotics compared to controls.
Outcomes
Symptoms via calendar checklist
Parents are instructed to record a (for this study) de-
signed daily checklist of clinical symptoms, which in-
clude coughing, wheezing, fever >38 °C, runny nose,
glue ear, rash, diarrhea, >3 h of crying within one day
(24 h). Table 1 shows the various symptoms, which
should be recorded by the parents. Descriptions standardize
the way of recording as much as possible. The checklists
are designed as a calendar and parents are requested
to return a list (at the end of) every month. As a motiv-
ation for returning the list, we send back a contemporary
Dutch magazine for young parents, monthly, after re-
ceiving their list.
At baseline, parents have to fill out an online question-
naire containing questions on demographics, comorbidity
and use of medication. This questionnaire includes: gesta-
tional age and birthweight of the child, maternal comor-
bidity (medication during pregnancy and delivery),
environmental factors (habitat, housing), parental smoking
Rutten et al. BMC Pediatrics  (2015) 15:204 Page 3 of 8
habits, siblings, pets, chronic diseases and hereditary dis-
eases, ethnicity, education.
Regarding the daily checklists, RTI’s and GITI's are
defined as follows: an episode of respiratory tract infection
includes at least two consecutive days of coughing and/or
wheezing, runny nose and/ or earache (with or without
secretion). An episode ends when the child is symptom-
free for at least two consecutive days. Diarrhea is defined
as increase in stool frequency to twice the usual number
per day, during at least two consecutive days. Parents also
report visits to the general practitioner because of respira-
tory or gastrointestinal symptoms of their child (since
particularly respiratory infection may have a confounding
effect, as antibiotic use and respiratory infections are so
common and closely related in early life) [39]. Parents are
extensively instructed by one of the investigators, at base-
line of the study, how to fill in the daily checklists and
how to interpret their child’s symptoms.
Symptoms via doctor’s diagnosis
Primary care visits and physicians-diagnoses during the
first year of life are recorded according to the Inter-
national Classification system of Primary Care (ICPC)
[40] and are traced through report of the computerized
medical files recorded by the general practitioner.
Visits to the physician are defined as the occurrence of
a “respiratory ICPC”, “gastrointestinal ICPC” or “derma-
tological ICPC”. For respiratory ICPC’s, these include
dyspnea (R02), wheezing (R03), cough (R05), acute upper
tract infection (R74), acute bronchi(oli)tis (R78), pneumonia
(R81), asthma like symptoms (R96), or other less prevalent
respiratory ICPC’s (breath problems [R04], sneeze [R07],
other symptoms of the nose [R08], symptoms of the throat
[R21], abnormal sputum [R25], concern about respiratory
illness [R27], acute laryngitis [R77], influenza [R88], other
infections of the airways [R83], and other respiratory
diseases [R99]). For gastrointestinal ICPC’s these include
infectious diarrhea (D70), vomiting (D10) and susceptible
gastro-intestinal infection (D73). Dermatological ICPC’s
include other symptoms/complaints of the skin (S21),
dry skin/flaking (S21.01). A child is considered to
have eczema when the doctors diagnose was estab-
lished and (1st or 2nd class) corticosteroids have been
prescribed. Prescription will be checked via pharma-
cist’s medication records. The incidence of colic is
recorded as ICPC infantile colic (A14).
Fig. 1 Overview of the sample time points and outcomes
Table 1 Description of symptoms
Coughing Your infant coughs several times a day and/or has coughing. Regularly there are signs of cold. Don’t record cough because of choking.
Wheezing During expiration you notice a whistling, wheezy sound coming from the lower airways. During expiration your child is trying
to squeeze the air outwards. Don’t record wheezing coming from or through the nose.
Fever >38 °C Clear from itself, whereby it is important you use a rectal thermometer, measure twice and the temperature is >38 °C on
both occasions.
Runny nose Signs of cold with white/yellow/green mucus running from the nose;
Glue ear Your child seems to have earache and/or grasps its ear (the ear frequently is high-colored or bends) and/or glue egresses
from the ear.
Rash More than one day existing skin-redness (spots, rash, pimples) on the face, arms or legs, trunk. Disease-symptoms are not
necessarily present. The rash can be eczema; eczema mostly is red, moistly, scaly and may itch. Infants cheeks are affected
mostly. When children grow up, elbow and knees are preferred sites.
Diarrhea Increase in stool frequency to twice the usual number per day, that continues more than one day. The content may be watery
or mucous.
>3 crying hours a day Clear from itself, whereby the total crying episodes add up to more than three hours a day (24 h) in total.
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Outpatient clinic visits
Shortly after the child’s first birthday, all children visit
the outpatient clinic of the recruiting hospital and par-
ents are asked to bring the collected, frozen fecal sam-
ples (on ice). Disease episodes (as to the respiratory tract
and gastrointestinal tract) during the first year of life are
discussed and documented. Any prescribed (systemic)
antibiotic treatments during the first year of life as well
as well as use of probiotics are recorded. At the end of
the visit, a venapuncture is performed to collect a 1 ml
blood sample. Serum is stored at −20 °C. At the end of the
study, IgG antibodies against Tetanus toxoid, Diphtheria
toxoid, Haemophilus influenza type B, and the capsular
polysaccharides of the pneumococcal 10-valent conjugate
vaccine will be determined. From the same blood sample,
specific IgE to food and inhalant allergens is determined
for objective evaluation of allergic sensitization.
Collection of fecal samples
Parents collect a total of 8 fecal samples during the first
year of life, and one sample at or around the 2nd birth-
day of the child. Directly after birth, nurses of the mater-
nity and neonatal wards collect the first fecal samples,
which are frozen at −20 °C. After discharge the parents
start collecting samples at home. Collection of stool sam-
ples is standardized (oral instruction by the investigators
at time of inclusion and there is a written instruction on
the daily checklist of symptoms, that parents receive).
Parents are instructed to sample directly from the dia-
per by means of stool collection vials (with integrated
spoons), and immediately freeze them in their home
freezers at a temperature of −18 to −20 °C. Moreover, in
order to be able to study transmission of microbiota
from the parents to the child, mother collects a stool
sample of her own within the first week after the delivery
and a buccal mucous membrane swab and a skin swab
from the mother and the father are taken at inclusion.
16S-23S IS profiling of the microbiota
The stool samples are subjected to microbiota compos-
ition profiling by means of a high-throughput bacterial
profiling technique (IS-pro, IS-Diagnostics, Amsterdam,
The Netherlands). This technique combines bacterial
species differentiation by the length of 16S-23S rRNA
interspace region with instant taxonomic classification
by phylum-specific fluorescent labeling of PCR-primers.
For amplification of IS regions, phylum-specific, fluo-
rescently labeled primers are designed, corresponding
to conserved regions within the 16S rRNA and 23S
rRNA genes [41]. The procedure consists of two multi-
plex PCRs, a combination of which provides very broad
coverage for Firmicutes, Actinobacteria, Fusobacteria
and Verrucomicrobia (FAFV), Bacteroidetes and Proteo-
bacteria. Amplifications are carried out on a GeneAmp
PCR system 9700 (Applied Biosystems, Foster City,
CA, USA).
Buccal mucous membrane and skin swabs are analyzed
by using the same IS-pro technique.
Data analysis
After pre-processing (IS-pro software suite, IS-Diagnostics),
each sample is represented by a microbial profile, consisting
of color-labelled peaks. Each peak is characterized by a spe-
cific IS fragment (measured as nucleotide length) and a
color related to a specific phylum group. The intensity of
peaks reflects the relative quantity of PCR product (mea-
sured in relative fluorescent units). We further consider
each peak as an operational taxonomic unit (OTU) and its
corresponding intensity as relative abundance. Intensity
values are log2 transformed when appropriate in order to
compact the range of variation in peak heights, to reduce
the dominance of abundant peaks and include less abun-
dant species of the microbiota in downstream analyses and
more related to the in vivo situation. This transformation
results in improved consistency of the estimated correlation
coefficient, lower impact of inter-run variation, and im-
proved detection of less prominent species. This conversion
is used in all downstream analyses, such as calculating
within-sample and between-sample microbial diversity [41].
Statistical analysis
We will evaluate the potential relationships between
antibiotic use in early life and the various (clinical) end-
points. Variables are verified for normal distribution and
t-tests will be used for testing the null hypothesis. Either
logistic regression analysis or cox regression analysis will
be applied to the data (appearance of the primary end-
point(s) will be recorded as specifically as possible), so
that odds ratios or hazard ratios and their 95 % confi-
dence interval can be presented for description of the
relationships. Multivariate models will be used to assess
confounders and confounding effects. We will perform
post hoc analyses to look for potential effects of the dif-
ferent antibiotic regimes. Outcomes may, possibly, be
classified into subgroups. According to antibiotic treat-
ment after the first two weeks, children will be grouped
based on the number of antibiotic courses during the
first year of life (0 / 1 / 2 or more courses). Within the
‘treatment groups’ a distinction can be made between
the class or spectrum of the prescribed antibiotics.
Microbiota composition will be described by means of
abundance, diversity and (dis)similarity. Diversity is cal-
culated using the Shannon index [42] and differences in
this index will be tested with Mann–Whitney U test.
Dissimilarities between samples, or between-sample di-
versity, are calculated as the cosine distance between
each pair of samples and analyzed with principal coord-
inate analysis (PCoA). All statistical analysis will be
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conducted using SPSS version 22.0 (SPSS Inc., Chicago, IL,
USA) and the vegan software package in R (Foundation for
Statistical Computing, Vienna, Austria).
Power calculation
The power of this observational cohort study and the
number of participants is based on one of the clinical rele-
vant primary endpoints: incidence of eczema after anti-
biotic exposure in early life. Eczema is the most common
inflammatory skin disease of childhood, affecting 5 to
20 % of children at any time. The cumulative prevalence
of eczema varies from 20 % in Northern Europe and the
USA to 5 % in the south-eastern Mediterranean [43]. In
high-risk populations in Northern Europe (e.g. infants
with a positive family history of atopy), the incidence of
eczema is increased and estimates 60 % [44]. Based on
these data, in this study the incidence of eczema in the
control group (healthy, non-antibiotic-treated infants) is
estimated 20 %, whereas in the antibiotic-treated group
(infants we assume at increased risk for developing ec-
zema) the incidence may rise to 35 %. This percentage, to
our opinion, reflects a slightly increased risk for develop-
ing eczema after antibiotic treatment in early life in a gen-
eral population of infants. Assuming a dropout rate of
15 %, a total of 450 children (150 antibiotics, 300 controls)
have to be included to demonstrate this difference
(20 %↔ 35 %) with a power of 80 % and an alpha of 5 %.
The prevalence of other disease outcomes is variable.
For example, prevalence rates of infantile colic vary be-
tween 5 and 40 % [45], and literature shows that almost
half of the children experience wheezing during the first
years of life [46]. So far, the effect of antibiotics (pro-
spectively investigated) on these frequencies is unknown.
Defining the size of potential differences to capture is
therefore limited.
Discussion
To the best of our knowledge, this is the first prospect-
ive observational cohort study, with a follow-up of one
year, addressing clinical outcomes after empiric anti-
biotic treatment in early life which at the same time in-
vestigates the development of intestinal microbiota
composition after this antibiotic exposure. Subsequently,
extensive clinical outcomes can be linked to microbiota
composition over time. This study includes a total of
450 infants, of whom 150 are exposed to antibiotic treat-
ment shortly after birth and 300 controls. Previous studies
addressing consequences of antibiotic treatment in early life
were hampered by a retrospective approach [11, 33, 39, 47],
divergent study populations [48], smaller sample sizes [17]
or a limited period of follow-up [34, 49].
By assessing an extended number of clinical parame-
ters in a fairly large group, and subsequently strictly se-
lected homogeneous subgroups of infants, bias due to
confounding factors such as mode of delivery and type
of feeding is expected to be reduced. Results from this
study may improve our understanding of the evolving
microbiota in term infants. Also, by collecting fecal sam-
ples at eight time points during the first year of life and
around the second birthday, long-term microbiota devel-
opment can be investigated.
The fact that children who are sick and receive anti-
biotic treatment may differ from healthy children, who
do not need antibiotic treatment at birth, is one of the
most important limitations of this study. However, to
our opinion, there are no opportunities to bypass this
problem, as ethical concerns prevent us from performing
a double blind randomized controlled trial. Another
limitation of this study may be the fact that bacterial
composition may change as a consequence of freezing
fecal samples. For example, levels of Bacteroidetes have
been shown to be reduced in frozen samples [3, 50, 51].
As all samples will be obtained by the parents and stored
in their home freezers, no information on potential dif-
ferences in storage conditions between samples can be
obtained. We try to minimize this variation by instruct-
ing (by one of the investigators) all parents on how to
collect the faecal samples, which makes the collection
procedure as standardized as possible. We do realize
that studying the microbiota composition of fecal sam-
ples may not be the best method to assess the general
composition and the effect of antibiotics in the gastro-
intestinal tract. Stool samples therefore are used as a
proxy for the study of the gut microbiota as these sam-
ples are easier to collect than biopsy samples and avoid
invasive procedures (and associated ethical issues). A
limitation of sampling the gut microbiota is that once
the sample is taken, alterations in the relative propor-
tions of various bacterial species can occur so that the
sample might no longer accurately reflect the compos-
ition of the microbiota in vivo by the time it is processed
[3]. This is a well-known problem with respect to mo-
lecular approach of microbiota composition and to date
it is impossible to collect biopsy samples from infants
(and healthy volunteers generally) on a large scale due to
the practical and ethical challenges indicated above [3].
IS-pro will be used to characterize the microbiota, be-
cause this technique has specifically been designed for
application in a clinical setting. It has been validated for
clinical diagnostics, which makes it fully reproducible
and the high-throughput nature of IS-pro makes analysis
of a large number of samples feasible. IS-pro comprises
two separate phylum-specific PCR reactions though,
which hampers direct comparisons of relative abun-
dances addressing all three phyla together [41]. Next to
that, IS-pro does not generate sequence data in the con-
ventional sense. This means IS-pro cannot achieve the
same level of detail as next-generation/whole genome
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sequencing techniques (e.g. Illumina), although sequence
data confirmed specificity of IS-pro in (currently) numer-
ous peaks, underlining the validity of the technique [41].
There is now sufficient evidence to conclude that anti-
biotic treatment in early life has a detrimental effect on
the gastrointestinal microbiota composition. However, it is
still unclear as to what extent the composition is disturbed
and for how long the gastrointestinal dysbiosis remains, if
and how microbiota composition will ‘normalize’ and what
the effects are on the developing immune system. These
findings can be important, since there is evidence that the
manipulation of infant microbiota by using pre-or probio-
tics can restore the ecological balance of the microbiota
[34, 52, 53]. If our hypothesis is proven with this study,
future studies should demonstrate if targeted intervention,
by using dietary supplements, pre- or probiotics or other-
wise, may have beneficial effects by limiting the gastro-
intestinal imbalance due to early antibiotic exposure.
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